3.45
Third Harmonic Bio Inc Borsa (THRD) Ultime notizie
Third Harmonic Bio Advances THB335 for Inflammatory Diseases - TipRanks
Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace
THB-335 counteracts cutaneous anaphylaxis in vivo - BioWorld Online
Third Harmonic Bio, Inc. (THRD) Loses -31.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Companies Like Third Harmonic Bio (NASDAQ:THRD) Are In A Position To Invest In Growth - Yahoo Finance
Third Harmonic Bio downgraded to Market Perform from Outperform at Raymond James - MSN
Third Harmonic Bio progresses THB335 to Phase 2 trial - MSN
Third Harmonic Bio, Inc. (THRD) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Down -39.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Third Harmonic Bio, Inc. (THRD) - Nasdaq
Third Harmonic stock rating cut by Raymond James - MSN
Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape - AOL
Raymond James downgrades Third Harmonic Bio on uncertainty for only asset - MSN
Morgan Stanley Downgrades Third Harmonic Bio to Equalweight From Overweight, Cuts Price Target to $5 From $20 - Marketscreener.com
Third Harmonic and Inventiva slash workforces - The Pharma Letter
Third Harmonic Bio progresses THB335 to Phase 2 trial By Investing.com - Investing.com Nigeria
Promising early data for Tonghua Dongbao’s obesity program - BioCentury
Morgan Stanley cuts Third Harmonic stock rating amid uncertainty - MSN
Finance Watch: Third Harmonic, Q32 Bio Cut Jobs To Focus On Lead Assets - News & Insights
Morgan Stanley cuts Third Harmonic stock rating amid uncertainty By Investing.com - Investing.com Canada
Third Harmonic Bio, Inc.: Hold Rating Amid Strategic Uncertainty and Safety Concerns - TipRanks
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Optimistic Buy Rating for Third Harmonic Bio Amid Promising Trial Results and Safety Concerns - TipRanks
Third Harmonic Bio Inc (THRD) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Stock market news: Fluence Energy -47.86%, Columbus McKinnon -40.83% among biggest losers during midday trading - Business Upturn
Third Harmonic stock rating cut by Raymond James By Investing.com - Investing.com South Africa
Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK - BioPharma Dive
Third Harmonic Bio Shares Slump After 50% Workforce Cut, Strategic Review Set -February 11, 2025 at 10:34 am EST - Marketscreener.com
Stock market today: Fluence Energy -46.44%, Columbus McKinnon -42.05% among biggest losers in early trading - Business Upturn
Third Harmonic Bio, Inc. Announces Restructuring Plan - TipRanks
Third Harmonic Bio stock tumbles after clinical trial results - Investing.com
Hain Celestial Group Inc’s Mixed Bag: Down -43.22% in 6 Months, Down -22.12% in 30 Days - The InvestChronicle
Third Harmonic Bio stock tumbles after clinical trial results By Investing.com - Investing.com South Africa
Third Harmonic halves headcount to take urticaria drug into phase 2 despite side effects - Fierce Biotech
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update - The Manila Times
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):